Ensysce Biosciences (ENSC) Prepaid Assets (2017 - 2025)
Ensysce Biosciences (ENSC) posted quarterly Prepaid Assets of $105091.0 for Q4 2025, down 93.88% year-over-year from $1.7 million in Q4 2024, and down 91.6% quarter-over-quarter from $1.3 million in Q3 2025.
Ensysce Biosciences (ENSC) Prepaid Assets (2017 - 2025) Analysis & Trends
Ensysce Biosciences (ENSC) has reported Prepaid Assets for 9 consecutive years, with $105091.0 the latest figure, recorded in Q4 2025.
- In Q4 2025, Prepaid Assets fell 93.88% year-over-year to $105091.0; the TTM figure through Dec 2025 stood at $105091.0 (down 93.88% YoY), while the FY2025 annual figure was $105091.0, down 93.88% from the prior year.
- Prepaid Assets eased to $105091.0 in Q4 2025 per ENSC's latest filing, from $1.3 million in the prior quarter.
- Across five years, Prepaid Assets topped out at $3.2 million in Q2 2022 and bottomed at $45206.0 in Q3 2023.
- Historically, Prepaid Assets has averaged $1.4 million across 5 years, with a median of $1.3 million in 2025.
- Annual changes were most pronounced in 2023 — Prepaid Assets tumbled 98.48% — and 2024, when it jumped 6877.19%.
- Ensysce Biosciences' Prepaid Assets stood at $2.9 million in 2021, then slumped by 36.98% to $1.8 million in 2022, then plunged by 42.21% to $1.1 million in 2023, then jumped by 60.95% to $1.7 million in 2024, then plunged by 93.88% to $105091.0 in 2025.
- Business Quant data shows ENSC's Prepaid Assets at $105091.0 in Q4 2025, $1.3 million in Q3 2025, and $1.9 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Ensysce Biosciences | 942,649.19 | -3.37 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 105,091.00 |
| Sep 30, 2025 | 1.25 Mn |
| Jun 30, 2025 | 1.87 Mn |
| Mar 31, 2025 | 1.33 Mn |
| Dec 31, 2024 | 1.72 Mn |
| Sep 30, 2024 | 3.15 Mn |
| Jun 30, 2024 | 1.19 Mn |
| Mar 31, 2024 | 1.20 Mn |
| Dec 31, 2023 | 1.07 Mn |
| Sep 30, 2023 | 45,206.00 |
| Jun 30, 2023 | 51,988.00 |
| Mar 31, 2023 | 151,016.00 |
| Dec 31, 2022 | 1.85 Mn |
| Sep 30, 2022 | 2.98 Mn |
| Jun 30, 2022 | 3.17 Mn |
| Mar 31, 2022 | 1.79 Mn |
| Dec 31, 2021 | 2.93 Mn |
| Sep 30, 2021 | 1.96 Mn |
| Jun 30, 2021 | 179,569.00 |
| Mar 31, 2021 | 190,400.00 |